Charles Schwab
NUVB icon

Charles Schwab’s Nuvation Bio NUVB Stock Holding History

Charles Schwab’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Buy
2,058,870
+66,419
+3% +$325K ﹤0.01% 2084
2026
Q1 		$8.55M Sell
1,992,451
-24,230
-1% -$135K ﹤0.01% 2181
2025
Q4 		$18.1M Sell
2,016,681
-38,814
-2% -$240K ﹤0.01% 1813
2025
Q3 		$7.61M Sell
2,055,495
-75,404
-4% -$205K ﹤0.01% 2238
2025
Q2 		$4.16M Buy
2,130,899
+226,758
+12% +$472K ﹤0.01% 2408
2025
Q1 		$3.35M Sell
1,904,141
-41,842
-2% -$95.2K ﹤0.01% 2438
2024
Q4 		$5.18M Buy
1,945,983
+551,968
+40% +$1.42M ﹤0.01% 2323
2024
Q3 		$3.19M Buy
1,394,015
+60,590
+5% +$185K ﹤0.01% 2569
2024
Q2 		$3.89M Buy
1,333,425
+185,398
+16% +$566K ﹤0.01% 2455
2024
Q1 		$4.18M Buy
1,148,027
+21,364
+2% +$41K ﹤0.01% 2345
2023
Q4 		$1.7M Buy
1,126,663
+84,510
+8% +$109K ﹤0.01% 2666
2023
Q3 		$1.4M Buy
1,042,153
+2,363
+0.2% +$3.93K ﹤0.01% 2694
2023
Q2 		$1.87M Buy
1,039,790
+85,989
+9% +$146K ﹤0.01% 2569
2023
Q1 		$1.58M Buy
953,801
+65,675
+7% +$133K ﹤0.01% 2585
2022
Q4 		$1.71M Sell
888,126
-74,617
-8% -$151K ﹤0.01% 2618
2022
Q3 		$2.16M Buy
962,743
+138,558
+17% +$396K ﹤0.01% 2564
2022
Q2 		$2.67M Sell
824,185
-116,852
-12% -$510K ﹤0.01% 2470
2022
Q1 		$4.95M Buy
941,037
+33,364
+4% +$187K ﹤0.01% 2282
2021
Q4 		$7.72M Buy
907,673
+212,255
+31% +$1.95M ﹤0.01% 2136
2021
Q3 		$6.91M Buy
695,418
+317,882
+84% +$2.88M ﹤0.01% 2221
2021
Q2 		$3.52M Buy
377,536
+82,092
+28% +$936K ﹤0.01% 2522
2021
Q1 		$3.09M Buy
+295,444
New +$3.3M ﹤0.01% 2529

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Charles Schwab's NUVB Position: Q2 2026 in Review

Charles Schwab increased its Nuvation Bio (NUVB) stake by 3.3% in Q2 2026, buying an estimated $325K and bringing the position to 2,058,870 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

Charles Schwab first reported a position in NUVB in Q1 2021 and has held it in 22 quarters since. The position peaked at $18.1M in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Charles Schwab held 2,058,870 shares of Nuvation Bio worth $11.7M as of Q2 2026.
  • Charles Schwab bought 66,419 Nuvation Bio shares in Q2 2026, an estimated $325K.
  • Nuvation Bio made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2084 holding.
  • Charles Schwab first reported a position in Nuvation Bio in Q1 2021 and has held it in 22 quarters since.
  • Charles Schwab's Nuvation Bio position peaked at $18.1M in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.